47,500 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 47,500 shares of the company's stock, valued at approximately $1,370,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Assenagon Asset Management S.A. boosted its position in shares of Apellis Pharmaceuticals by 191.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company's stock worth $61,845,000 after buying an additional 1,409,707 shares during the period. Iron Triangle Partners LP bought a new stake in Apellis Pharmaceuticals during the 1st quarter worth about $32,329,000. Fiera Capital Corp boosted its stake in shares of Apellis Pharmaceuticals by 47.7% during the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company's stock worth $53,750,000 after buying an additional 452,753 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company's stock valued at $9,177,000 after acquiring an additional 190,420 shares in the last quarter. Finally, Redmile Group LLC bought a new position in shares of Apellis Pharmaceuticals in the first quarter valued at $9,111,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Price Performance

APLS stock traded down $0.48 during mid-day trading on Tuesday, reaching $28.08. 9,853,621 shares of the company traded hands, compared to its average volume of 1,761,444. The company has a fifty day moving average price of $31.81 and a 200-day moving average price of $37.40. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18. Apellis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $73.80. The company has a market capitalization of $3.42 billion, a P/E ratio of -9.26 and a beta of 0.87.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 37,000 shares of the company's stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now directly owns 100,000 shares in the company, valued at $3,623,000. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.80% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on APLS shares. Wells Fargo & Company cut their price target on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an "equal weight" rating for the company in a research note on Tuesday, September 24th. JPMorgan Chase & Co. cut their target price on Apellis Pharmaceuticals from $64.00 to $57.00 and set an "overweight" rating for the company in a research report on Friday, September 13th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $25.00 price target on shares of Apellis Pharmaceuticals in a research note on Monday. Robert W. Baird cut their price objective on shares of Apellis Pharmaceuticals from $96.00 to $92.00 and set an "outperform" rating for the company in a research report on Monday, September 23rd. Finally, Scotiabank initiated coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $35.00 price objective for the company. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $65.41.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).